Since 2020, Relay Therapeutics Inc. has been studying RLY-4008, a drug that if approved could treat about 1,000 Americans annually with a form of bile duct cancer ... for the National Organization for ...

Cash and cash equivalents totaled €96.0 million as of September 30, 2024€59.7 million in revenues for the nine months ended September 30, 2024, ...

Cholangiocarcinoma is classically described as an irregular narrowing of the bile duct with shouldered scalloped margins. The stricture usually causes a high-grade or complete obstruction with ...

CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or ...